ATE326265T1 - Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte - Google Patents

Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte

Info

Publication number
ATE326265T1
ATE326265T1 AT00978330T AT00978330T ATE326265T1 AT E326265 T1 ATE326265 T1 AT E326265T1 AT 00978330 T AT00978330 T AT 00978330T AT 00978330 T AT00978330 T AT 00978330T AT E326265 T1 ATE326265 T1 AT E326265T1
Authority
AT
Austria
Prior art keywords
dhea
calcitonin
treatment
bone mineral
mineral density
Prior art date
Application number
AT00978330T
Other languages
English (en)
Inventor
Kenneth E Schwartz
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Application granted granted Critical
Publication of ATE326265T1 publication Critical patent/ATE326265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00978330T 1999-11-12 2000-11-13 Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte ATE326265T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16508999P 1999-11-12 1999-11-12
US09/710,729 US6605591B1 (en) 1999-11-12 2000-11-10 Treatment of subnormal bone mineral density

Publications (1)

Publication Number Publication Date
ATE326265T1 true ATE326265T1 (de) 2006-06-15

Family

ID=26861107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978330T ATE326265T1 (de) 1999-11-12 2000-11-13 Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte

Country Status (16)

Country Link
US (3) US6605591B1 (de)
EP (1) EP1231983B1 (de)
JP (1) JP2003514026A (de)
KR (1) KR20020063183A (de)
CN (1) CN1411386A (de)
AT (1) ATE326265T1 (de)
AU (1) AU784160B2 (de)
BR (1) BR0015534A (de)
CA (1) CA2390431A1 (de)
DE (1) DE60028074D1 (de)
IL (1) IL149532A0 (de)
MX (1) MXPA02004776A (de)
NO (1) NO20022246L (de)
NZ (1) NZ518791A (de)
RU (1) RU2002115815A (de)
WO (1) WO2001035975A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
DE60233485D1 (de) 2001-05-25 2009-10-08 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
EP1605824A2 (de) 2003-03-25 2005-12-21 Imaging Therapeutics, Inc. Verfahren zur kompensation der bildgebenden technik bei der bearbeitung von röntgenaufnahmen
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
US20080058613A1 (en) * 2003-09-19 2008-03-06 Imaging Therapeutics, Inc. Method and System for Providing Fracture/No Fracture Classification
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
PT2460515T (pt) * 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
AU2009253839B2 (en) * 2008-06-03 2011-07-28 John Ray Biffin A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU743121B2 (en) 1996-11-25 2002-01-17 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
KR20000071039A (ko) * 1997-02-13 2000-11-25 비숍 찰스 더블유. 비타민 ｄ 화합물의 표적화된 치료학적 전달
CN100544726C (zh) 1999-03-18 2009-09-30 基因实验室技术公司 Dhea制剂及方法
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density

Also Published As

Publication number Publication date
WO2001035975A2 (en) 2001-05-25
RU2002115815A (ru) 2004-02-27
KR20020063183A (ko) 2002-08-01
US20050113301A1 (en) 2005-05-26
WO2001035975A3 (en) 2001-12-27
DE60028074D1 (de) 2006-06-22
US7612034B2 (en) 2009-11-03
EP1231983B1 (de) 2006-05-17
US20030158159A1 (en) 2003-08-21
CA2390431A1 (en) 2001-05-25
AU1580201A (en) 2001-05-30
EP1231983A2 (de) 2002-08-21
CN1411386A (zh) 2003-04-16
NZ518791A (en) 2004-03-26
JP2003514026A (ja) 2003-04-15
NO20022246L (no) 2002-07-03
BR0015534A (pt) 2002-07-02
AU784160B2 (en) 2006-02-16
IL149532A0 (en) 2002-11-10
MXPA02004776A (es) 2003-01-28
US6854468B2 (en) 2005-02-15
US6605591B1 (en) 2003-08-12
NO20022246D0 (no) 2002-05-10

Similar Documents

Publication Publication Date Title
DE60028074D1 (de) Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
PL332413A1 (en) Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
ATE303817T1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TW200505473A (en) Compositions and methods for treatment of psoriasis
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
AU6083301A (en) Treating eczema and/or psoriasis
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DE69008258T2 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
DE69716434D1 (de) Verwendung von lysin zur behandlung des haarausfalls
GB2331301C (en) Galanin
AU2003248816A8 (en) Composition for lessening malodors during hair treatment and hair removal and method of use
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
ATE282398T1 (de) Verfahren zum dauerwellen von menschlichen haaren
DE60129725D1 (de) Schwefel analoge von 21-hydroxy-6,19-oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss
ATE345138T1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
GB9709769D0 (en) Composition and method of treating skin disorders
DE69828553D1 (de) Gerät zur behandlung von harnwegs- und anderen körperstenosen
ATA144696A (de) Vorrichtung zur behandlung von schenkenhalsfrakturen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties